In the webinar, 5 Keys to Success in the New Patient Economy, you'll learn tips and strategies for transforming your patient engagement model.
Drugmakers test out virtual reality, partner with companies like Spotify, and go for the cinematic at Cannes Lions.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.
The truth is, biopharma marketing and behavioral psychology have a lot in common. Ultimately, both aim to nudge people to make a medical or lifestyle change that could positively impact their health.
Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?
It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.
Maybe we have just forgotten the true reason why marketing exists in organizations.
At the MM&M Transforming Healthcare conference, Iyengar told attendees how to take into account a consumer's behavior and emotion when marketing medical products.
Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.
Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.
Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.
If you truly understand who your high writers and compliant patients are, you'll understand when and how to communicate with prospects that look and act like them.
Maybe it's time for pharma and healthcare marketers to put all the "patient-centric" talk on the shelf — not the actual paying-attention-to-patients part of it, but the trumpeting of it as the most noble of life-science virtues.
The motivating force behind My GI Health met initial resistance. After all, it came from a company executive who professed that his goal was to benefit all companies within that therapeutic area.
Tom McCourt says he's "a marketing guy who hopefully understands a little about drug development" even as he guided drugs like Prilosec to market.
There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.
Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug
One conversation with a real patient—followed by many more conversations with more patients—helped me see how important our work can be in the eyes of patients.
Finn Partners surveyed 1,000 adults to understand how often young Americans change doctors and how they talk to pharmacists.
If we as an industry want to be customer-centric in the same way that Apple or Amazon is, we need to change nearly everything about how we do business.
When it came to the issue of patient-centricity, each of us harbored at least a hint of cynicism.
Providing financial assistance to patients has become a common refrain in drugmakers' defense of high-priced drugs.
Life-sciences companies often behave as though focusing on patient needs is simply a matter of asking, "How can we provide patients with more services?
Although the industry wants to help patients get healthy - and wants to be a critical part in that process - there's a delicate balance to strike between selling product and achieving healthier outcomes.
Many patients allow doctors to access their social-media accounts; Turing will reportedly lower the price of Daraprim by 10%; WebMD reports boost in traffic
Patient portals are an underutilized resource for a population hungry for health information.
Work hard to get everyone in your company to understand what you can learn from social listening—you'll know you're successful when inquisitive minds throughout the company start asking you the question, "Can we find out what patients are saying about this brand online?"
The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.
Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker